Clinical trials
Completed Ureteral Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2021 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 33 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| Dr Anders Ullén | 2 |
| Eli Lilly and Company | 2 |
| M.D. Anderson Cancer Center | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Achieve Life Sciences | 1 |
| Altor BioScience | 1 |
| Asan Medical Center | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Astellas Pharma Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ureteral Neoplasms | 33 |
| Urinary Bladder Neoplasms | 25 |
| Urethral Neoplasms | 21 |
| Carcinoma, Transitional Cell | 16 |
| Kidney Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Carcinoma, Renal Cell | 3 |
| Lung Neoplasms | 3 |
| Pancreatic Neoplasms | 3 |
| Prostatic Neoplasms | 3 |
Trials
Showing 51 to 33 of 33. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.